GlassScriptPhysician profile
Shane R Oneill
NPI 1477548113
$3,464.44
in general payments reported to CMS, 2019-2025
18 companies · $646 in 2025
The $646 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $254 · 2021: $506 · 2022: $587 · 2023: $601 · 2024: $606 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,853.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,271.07 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Kowa Pharmaceuticals America, INC. | $450.13 | 2019-2023 | Livalo, Seglentis |
| Astrazeneca Pharmaceuticals LP | $330.35 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $304.53 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $254.66 | 2019-2025 | |
| Antares Pharma, INC. | $172.15 | 2020-2023 | Nocdurna, Tlando, Xyosted |
| Abbott Laboratories | $170.20 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $105.60 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $72.57 | 2020-2024 | Zepbound, Mounjaro |
| Sanofi Pasteur INC. | $58.21 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $52.42 | 2022-2023 | |
| Exact Sciences Corporation | $49.94 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $42.79 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $39.22 | 2020-2021 | |
| Strata Skin Sciences, INC. | $32.56 | 2025 | Xtrac |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $20.90 | 2024 | Tirosint, Licart |
| Tolmar, INC. | $20.84 | 2025 | Jatenzo |
| Phathom Pharmaceuticals, INC. | $16.30 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Oneill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.